- Home
- VRCA vs PRLD Comparison
VRCA vs PRLD Comparison
Compare VRCA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- PRLD
- Stock Information
- Founded
- VRCA 2013
- PRLD 2016
- Country
- VRCA United States
- PRLD United States
- Employees
- VRCA N/A
- PRLD N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- VRCA Health Care
- PRLD Health Care
- Exchange
- VRCA Nasdaq
- PRLD Nasdaq
- Market Cap
- VRCA 43.0M
- PRLD 50.1M
- IPO Year
- VRCA 2018
- PRLD 2020
- Fundamental
- Price
- VRCA $0.54
- PRLD $0.86
- Analyst Decision
- VRCA Hold
- PRLD Strong Buy
- Analyst Count
- VRCA 5
- PRLD 2
- Target Price
- VRCA $6.00
- PRLD $4.50
- AVG Volume (30 Days)
- VRCA 263.8K
- PRLD 137.5K
- Earning Date
- VRCA 05-13-2025
- PRLD 05-06-2025
- Dividend Yield
- VRCA N/A
- PRLD N/A
- EPS Growth
- VRCA N/A
- PRLD N/A
- EPS
- VRCA N/A
- PRLD N/A
- Revenue
- VRCA $7,179,000.00
- PRLD $7,000,000.00
- Revenue This Year
- VRCA $127.85
- PRLD N/A
- Revenue Next Year
- VRCA $105.09
- PRLD N/A
- P/E Ratio
- VRCA N/A
- PRLD N/A
- Revenue Growth
- VRCA N/A
- PRLD N/A
- 52 Week Low
- VRCA $0.38
- PRLD $0.61
- 52 Week High
- VRCA $9.36
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- VRCA 43.40
- PRLD 50.46
- Support Level
- VRCA $0.49
- PRLD $0.77
- Resistance Level
- VRCA $0.73
- PRLD $1.00
- Average True Range (ATR)
- VRCA 0.07
- PRLD 0.10
- MACD
- VRCA -0.01
- PRLD -0.01
- Stochastic Oscillator
- VRCA 10.77
- PRLD 33.33
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.